메뉴 건너뛰기




Volumn 6, Issue 2, 2016, Pages

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: A network meta-analysis

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT;

EID: 84960444156     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009421     Document Type: Article
Times cited : (51)

References (60)
  • 3
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
    • (2015) Diabetes Care , vol.38 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 4
    • 84961289782 scopus 로고    scopus 로고
    • Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes
    • Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254-60.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 254-260
    • Shiramoto, M.1    Eto, T.2    Irie, S.3
  • 5
    • 84905721701 scopus 로고    scopus 로고
    • Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    • Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-6.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 873-876
    • Steinstraesser, A.1    Schmidt, R.2    Bergmann, K.3
  • 6
    • 84908179629 scopus 로고    scopus 로고
    • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
    • Riddle MC, Bolli GB, Ziemen M, et al., EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-62.
    • (2014) Diabetes Care , vol.37 , pp. 2755-2762
    • Riddle, M.C.1    Bolli, G.B.2    Ziemen, M.3
  • 7
    • 84910033227 scopus 로고    scopus 로고
    • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents andbasal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
    • Yki-Järvinen H, Bergenstal R, Ziemen M, et al., EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents andbasal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-43.
    • (2014) Diabetes Care , vol.37 , pp. 3235-3243
    • Yki-Järvinen, H.1    Bergenstal, R.2    Ziemen, M.3
  • 8
    • 84924731879 scopus 로고    scopus 로고
    • New insulin glargine 300 U/mL compared with glargine 100 U/mL ininsulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)
    • Bolli GB, Riddle MC, Bergenstal RM, et al., on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/mL compared with glargine 100 U/mL ininsulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-94.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 386-394
    • Bolli, G.B.1    Riddle, M.C.2    Bergenstal, R.M.3
  • 11
    • 66549123433 scopus 로고    scopus 로고
    • DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes
    • Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-13.
    • (2009) Diabetes Care , vol.32 , pp. 1007-1013
    • Buse, J.B.1    Wolffenbuttel, B.H.2    Herman, W.H.3
  • 12
    • 73349140858 scopus 로고    scopus 로고
    • Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study
    • Fritsche A, Larbig M, Owens D, et al. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010;12:115-23.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 115-123
    • Fritsche, A.1    Larbig, M.2    Owens, D.3
  • 13
    • 77957279506 scopus 로고    scopus 로고
    • Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: Initiate and progressively advance insulin therapy in type 2 diabetes
    • Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:967-75.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 967-975
    • Jain, S.M.1    Mao, X.2    Escalante-Pulido, M.3
  • 14
    • 33845317568 scopus 로고    scopus 로고
    • Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
    • Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-32.
    • (2006) Exp Clin Endocrinol Diabetes , vol.114 , pp. 527-532
    • Kann, P.H.1    Wascher, T.2    Zackova, V.3
  • 15
    • 33748263029 scopus 로고    scopus 로고
    • Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. Basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    • Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat 2006;20:145-52.
    • (2006) J Diabetes Complicat , vol.20 , pp. 145-152
    • Kazda, C.1    Hulstrunk, H.2    Helsberg, K.3
  • 16
    • 79952384658 scopus 로고    scopus 로고
    • A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: A randomized, open-label study
    • Ligthelm RJ, Gylvin T, De Luzio T, et al. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract 2011;17:41-50.
    • (2011) Endocr Pract , vol.17 , pp. 41-50
    • Ligthelm, R.J.1    Gylvin, T.2    De Luzio, T.3
  • 17
    • 12844265257 scopus 로고    scopus 로고
    • Initiating insulin therapy in type 2 Diabetes: A comparison of biphasic and basal insulin analogs
    • Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5.
    • (2005) Diabetes Care , vol.28 , pp. 260-265
    • Raskin, P.1    Allen, E.2    Hollander, P.3
  • 18
    • 84871445772 scopus 로고    scopus 로고
    • Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: Twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine
    • Riddle MC, Vlajnic A, Jones B, et al. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine. Diabetes 2011;60(Suppl 1):A113.
    • (2011) Diabetes , vol.60 , pp. A113
    • Riddle, M.C.1    Vlajnic, A.2    Jones, B.3
  • 19
    • 37449017989 scopus 로고    scopus 로고
    • 1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison
    • 1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64.
    • (2007) Clin Ther , vol.29 , pp. 2349-2364
    • Robbins, D.C.1    Beisswenger, P.J.2    Ceriello, A.3
  • 20
    • 38149073314 scopus 로고    scopus 로고
    • Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    • Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5.
    • (2008) Diabetes Care , vol.31 , pp. 20-25
    • Rosenstock, J.1    Ahmann, A.J.2    Colon, G.3
  • 21
    • 72549114224 scopus 로고    scopus 로고
    • Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: An open-label, multinational RCT
    • Strojek K, Bebakar WMW, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2887-2894
    • Strojek, K.1    Bebakar, W.M.W.2    Khutsoane, D.T.3
  • 24
    • 0038131919 scopus 로고    scopus 로고
    • Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial
    • Fritsche A, Schweitzer MA, Haring H-U, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9.
    • (2003) Ann Intern Med , vol.138 , pp. 952-959
    • Fritsche, A.1    Schweitzer, M.A.2    Haring, H.-U.3
  • 25
    • 0038292180 scopus 로고    scopus 로고
    • A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes
    • Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96.
    • (2003) Horm Metab Res , vol.35 , pp. 189-196
    • Massi Benedetti, M.1    Humburg, E.2    Dressler, A.3
  • 26
    • 0242269000 scopus 로고    scopus 로고
    • The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    • Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
    • (2003) Diabetes Care , vol.26 , pp. 3080-3086
    • Riddle, M.C.1    Rosenstock, J.2    Gerich, J.3
  • 27
    • 0034827469 scopus 로고    scopus 로고
    • Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
    • Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
    • (2001) Diabetes Care , vol.24 , pp. 631-636
    • Rosenstock, J.1    Schwartz, S.L.2    Clark, C.M.3
  • 28
    • 68449099924 scopus 로고    scopus 로고
    • Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study
    • Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009;52:1778-88.
    • (2009) Diabetologia , vol.52 , pp. 1778-1788
    • Rosenstock, J.1    Fonseca, V.2    McGill, J.B.3
  • 29
    • 33244479164 scopus 로고    scopus 로고
    • Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
    • Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51.
    • (2006) Diabetologia , vol.49 , pp. 442-451
    • Yki-Järvinen, H.1    Kauppinen-Makelin, R.2    Tiikkainen, M.3
  • 30
    • 84859921058 scopus 로고    scopus 로고
    • Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
    • Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507.
    • (2012) Lancet , vol.379 , pp. 1498-1507
    • Garber, A.J.1    King, A.B.2    Del Prato, S.3
  • 31
    • 84889648892 scopus 로고    scopus 로고
    • Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial
    • Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42.
    • (2013) Diabetes Care , vol.36 , pp. 2536-2542
    • Gough, S.C.1    Bhargava, A.2    Jain, R.3
  • 32
    • 84875444482 scopus 로고    scopus 로고
    • The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
    • Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-64.
    • (2013) Diabetes Care , vol.36 , pp. 858-864
    • Meneghini, L.1    Atkin, S.L.2    Gough, S.C.L.3
  • 33
    • 84869842163 scopus 로고    scopus 로고
    • Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
    • Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71.
    • (2012) Diabetes Care , vol.35 , pp. 2464-2471
    • Zinman, B.1    Philis-Tsimikas, A.2    Cariou, B.3
  • 34
    • 84884502135 scopus 로고    scopus 로고
    • Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
    • Zinman B, De Vries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol 2013;1:123-31.
    • (2013) Lancet Diabetes Endocrinol , vol.1 , pp. 123-131
    • Zinman, B.1    De Vries, J.H.2    Bode, B.3
  • 35
    • 57649230070 scopus 로고    scopus 로고
    • A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
    • Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87.
    • (2008) Clin Ther , vol.30 , pp. 1976-1987
    • Hollander, P.1    Cooper, J.2    Bregnhoj, J.3
  • 36
    • 84879799134 scopus 로고    scopus 로고
    • Once-daily initiation of basal insulin as add-on to metformin: A 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
    • Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:729-36.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 729-736
    • Meneghini, L.1    Kesavadev, J.2    Demissie, M.3
  • 37
    • 70350605350 scopus 로고    scopus 로고
    • Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
    • Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8.
    • (2009) Diabetes Metab Res Rev , vol.25 , pp. 542-548
    • Raskin, P.1    Gylvin, T.2    Weng, W.3
  • 38
    • 39049105019 scopus 로고    scopus 로고
    • A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
    • (2008) Diabetologia , vol.51 , pp. 408-416
    • Rosenstock, J.1    Davies, M.2    Home, P.D.3
  • 39
    • 77954255771 scopus 로고    scopus 로고
    • A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs
    • Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8.
    • (2010) Diabetes Care , vol.33 , pp. 1176-1178
    • Swinnen, S.G.1    Dain, M.P.2    Aronson, R.3
  • 40
    • 35548947584 scopus 로고    scopus 로고
    • Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    • Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
    • (2007) N Engl J Med , vol.357 , pp. 1716-1730
    • Holman, R.R.1    Thorne, K.I.2    Farmer, A.J.3
  • 41
    • 58149177354 scopus 로고    scopus 로고
    • Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial
    • Liebl A, Prager R, Binz K, et al., PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 45-52
    • Liebl, A.1    Prager, R.2    Binz, K.3
  • 42
    • 12744274870 scopus 로고    scopus 로고
    • Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes
    • Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 56-64
    • Haak, T.1    Tiengo, A.2    Draeger, E.3
  • 43
    • 33746391488 scopus 로고    scopus 로고
    • A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74.
    • (2006) Diabetes Care , vol.29 , pp. 1269-1274
    • Hermansen, K.1    Davies, M.2    Derezinski, T.3
  • 44
    • 48249139906 scopus 로고    scopus 로고
    • Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial
    • Montañana CF, Herrero CH, Fernandez MR. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23.
    • (2008) Diabet Med , vol.25 , pp. 916-923
    • Montañana, C.F.1    Herrero, C.H.2    Fernandez, M.R.3
  • 45
    • 33845236398 scopus 로고    scopus 로고
    • Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
    • Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81.
    • (2006) Clin Ther , vol.28 , pp. 1569-1581
    • Philis-Tsimikas, A.1    Charpentier, G.2    Clauson, P.3
  • 46
    • 6944244979 scopus 로고    scopus 로고
    • Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes
    • Raslová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
    • (2004) Diabetes Res Clin Pract , vol.66 , pp. 193-201
    • Raslová, K.1    Bogoev, M.2    Raz, I.3
  • 47
    • 12844276465 scopus 로고    scopus 로고
    • Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
    • Janka H, Plewe G, Riddle M, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.
    • (2005) Diabetes Care , vol.28 , pp. 254-259
    • Janka, H.1    Plewe, G.2    Riddle, M.3
  • 48
    • 77955094348 scopus 로고    scopus 로고
    • Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: Results from the durable trial
    • Lee LJ, Fahrbach JL, Nelson LM, et al. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial. Diabetes Res Clin Pract 2010;89:157-66.
    • (2010) Diabetes Res Clin Pract , vol.89 , pp. 157-166
    • Lee, L.J.1    Fahrbach, J.L.2    Nelson, L.M.3
  • 49
    • 33846254561 scopus 로고    scopus 로고
    • Basal insulin or premix analogue therapy in type 2 diabetes patients
    • Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007;18:56-62.
    • (2007) Eur J Intern Med , vol.18 , pp. 56-62
    • Raskin, P.R.1    Hollander, P.A.2    Lewin, A.3
  • 50
    • 0033867021 scopus 로고    scopus 로고
    • Less nocturnalhypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group
    • Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnalhypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.
    • (2000) Diabetes Care , vol.23 , pp. 1130-1136
    • Yki-Järvinen, H.1    Dressler, A.2    Ziemen, M.3
  • 51
    • 84929019522 scopus 로고    scopus 로고
    • New insulinglargine 300 Units mL-1 provides a more even activity profile and prolongedglycemic control at steady state compared with insulin glargine 100 Units mL-1
    • Becker RH, Dahmen R, Bergmann K, et al. New insulinglargine 300 Units mL-1 provides a more even activity profile and prolongedglycemic control at steady state compared with insulin glargine 100 Units mL-1. Diabetes Care 2015;38:637-43.
    • (2015) Diabetes Care , vol.38 , pp. 637-643
    • Becker, R.H.1    Dahmen, R.2    Bergmann, K.3
  • 52
    • 47649100195 scopus 로고    scopus 로고
    • Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis
    • Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-9.
    • (2008) Diabetes Res Clin Pract , vol.81 , pp. 184-189
    • Monami, M.1    Marchionni, N.2    Mannucci, E.3
  • 53
    • 77955031968 scopus 로고    scopus 로고
    • Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
    • Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-9.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 772-779
    • Home, P.D.1    Fritsche, A.2    Schinzel, S.3
  • 54
    • 84939572199 scopus 로고    scopus 로고
    • Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
    • Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859-67.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 859-867
    • Ritzel, R.1    Roussel, R.2    Bolli, G.B.3
  • 55
    • 84887200674 scopus 로고    scopus 로고
    • A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
    • Freemantle N, Balkau B, Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013;15:1120-7.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 1120-1127
    • Freemantle, N.1    Balkau, B.2    Home, P.D.3
  • 56
    • 84908689468 scopus 로고    scopus 로고
    • The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes
    • Edelman SV, Blose JS. The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes. Diabetes Educ 2014;40:269-79.
    • (2014) Diabetes Educ , vol.40 , pp. 269-279
    • Edelman, S.V.1    Blose, J.S.2
  • 57
    • 84877340173 scopus 로고    scopus 로고
    • A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function
    • Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013;15:546-57.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 546-557
    • Brod, M.1    Wolden, M.2    Christensen, T.3
  • 58
    • 84890313541 scopus 로고    scopus 로고
    • Understanding the economic burden of nonsevere nocturnal hypoglycemic events: Impact on work productivity, disease management, and resource utilization
    • Brod M, Wolden M, Christensen T, et al. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health 2013;16:1140-9.
    • (2013) Value Health , vol.16 , pp. 1140-1149
    • Brod, M.1    Wolden, M.2    Christensen, T.3
  • 59
    • 84898648419 scopus 로고    scopus 로고
    • Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: A meta-analysis of 5 randomized begin trials
    • Rodbard HW, Gough S, Lane W, et al. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract 2014;20:285-92.
    • (2014) Endocr Pract , vol.20 , pp. 285-292
    • Rodbard, H.W.1    Gough, S.2    Lane, W.3
  • 60
    • 84937817361 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
    • Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015;52:649-62.
    • (2015) Acta Diabetol , vol.52 , pp. 649-662
    • Rys, P.1    Wojciechowski, P.2    Rogoz-Sitek, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.